

# Andrew M Evens

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/5698032/andrew-m-evens-publications-by-citations.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

261  
papers

10,487  
citations

51  
h-index

97  
g-index

277  
ext. papers

12,134  
ext. citations

4.8  
avg. IF

5.73  
L-index

#	Paper	IF	Citations
261	Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. <i>Blood</i> , <b>2009</b> , 113, 4834-40	2.2	718
260	Genetic and Functional Drivers of Diffuse Large B-Cell Lymphoma. <i>Cell</i> , <b>2017</b> , 171, 481-494.e15	56.2	499
259	The genetic landscape of mutations in Burkitt lymphoma. <i>Nature Genetics</i> , <b>2012</b> , 44, 1321-5	36.3	422
258	Genetic heterogeneity of diffuse large B-cell lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2013</b> , 110, 1398-403	11.5	419
257	Pure red-cell aplasia and epoetin therapy. <i>New England Journal of Medicine</i> , <b>2004</b> , 351, 1403-8	59.2	338
256	Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. <i>Blood</i> , <b>2014</b> , 124, 2354-61	2.2	306
255	An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. <i>Annals of Oncology</i> , <b>2013</b> , 24, 257-63	10.3	249
254	Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 1038-46	2.2	243
253	Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. <i>Annals of Oncology</i> , <b>2011</b> , 22, 1170-1180	10.3	237
252	Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. <i>Bone Marrow Transplantation</i> , <b>2007</b> , 40, 451-6	4.4	185
251	US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2020-7	2.2	184
250	T-cell non-Hodgkin lymphoma. <i>Blood</i> , <b>2006</b> , 107, 1255-64	2.2	178
249	Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies. <i>Current Hematologic Malignancy Reports</i> , <b>2013</b> , 8, 173-83	4.4	177
248	Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. <i>Cancer</i> , <b>2007</b> , 109, 1532-5	6.4	177
247	Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. <i>Bone Marrow Transplantation</i> , <b>2007</b> , 39, 425-9	4.4	173
246	Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs. <i>Blood</i> , <b>2010</b> , 116, e118-27	2.2	167
245	Oxidative stress and apoptosis: a new treatment paradigm in cancer. <i>Frontiers in Bioscience - Landmark</i> , <b>2006</b> , 11, 300-12	2.8	166

244	The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future. <i>Leukemia Research</i> , <b>2004</b> , 28, 891-900	2.7	148
243	Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. <i>Leukemia Research</i> , <b>2007</b> , 31, 599-604	2.7	136
242	Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience. <i>Blood</i> , <b>2016</b> , 128, 2199-2205	2.2	135
241	Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project. <i>Bone Marrow Transplantation</i> , <b>2007</b> , 40, 185-92	4.4	125
240	Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations. <i>Current Treatment Options in Oncology</i> , <b>2012</b> , 13, 122-36	5.4	120
239	Primary CNS posttransplant lymphoproliferative disease (PTLD): an international report of 84 cases in the modern era. <i>American Journal of Transplantation</i> , <b>2013</b> , 13, 1512-22	8.7	116
238	A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. <i>Blood</i> , <b>2012</b> , 119, 692-5	2.2	113
237	Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project. <i>British Journal of Haematology</i> , <b>2006</b> , 135, 642-50	4.5	112
236	Post-transplantation lymphoproliferative disorders: diagnosis, prognosis, and current approaches to therapy. <i>Current Oncology Reports</i> , <b>2010</b> , 12, 383-94	6.3	108
235	Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. <i>JAMA - Journal of the American Medical Association</i> , <b>2006</b> , 296, 2558-60	27.4	107
234	The Genetic Basis of Hepatosplenic T-cell Lymphoma. <i>Cancer Discovery</i> , <b>2017</b> , 7, 369-379	24.4	105
233	Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 113-22	12.9	101
232	Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 1653-9	2.2	94
231	Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. <i>Annals of Oncology</i> , <b>2014</b> , 25, 2211-2217	10.3	90
230	The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. <i>British Journal of Haematology</i> , <b>2013</b> , 161, 76-86	4.5	86
229	The Research on Adverse Drug Events and Reports (RADAR) project. <i>JAMA - Journal of the American Medical Association</i> , <b>2005</b> , 293, 2131-40	27.4	86
228	Rust and corrosion in hematopoietic stem cell transplantation: the problem of iron and oxidative stress. <i>Bone Marrow Transplantation</i> , <b>2004</b> , 34, 561-71	4.4	83
227	Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. <i>Blood</i> , <b>2005</b> , 106, 3343-7	2.2	83

226	PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 3354-65	12.9	80
225	Treatment of Hodgkin lymphoma: the past, present, and future. <i>Nature Clinical Practice Oncology</i> , <b>2008</b> , 5, 543-56		75
224	Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia. <i>Bone Marrow Transplantation</i> , <b>2006</b> , 37, 997-1001	4.4	71
223	Mitochondrial-mediated apoptosis in lymphoma cells by the diterpenoid lactone andrographolide, the active component of <i>Andrographis paniculata</i> . <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 4755-68	12.9	68
222	Analysis of very elderly (80 years) non-hodgkin lymphoma: impact of functional status and co-morbidities on outcome. <i>British Journal of Haematology</i> , <b>2012</b> , 156, 196-204	4.5	67
221	Racial disparities in Hodgkin's lymphoma: a comprehensive population-based analysis. <i>Annals of Oncology</i> , <b>2012</b> , 23, 2128-2137	10.3	66
220	Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998). <i>Leukemia</i> , <b>2015</b> , 29, 886-94	10.7	65
219	Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 4132-9	2.2	63
218	Pemetrexed in the treatment of relapsed/refractory primary central nervous system lymphoma. <i>Cancer</i> , <b>2012</b> , 118, 3743-8	6.4	62
217	G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. <i>British Journal of Haematology</i> , <b>2007</b> , 137, 545-52	4.5	61
216	Motexafin gadolinium generates reactive oxygen species and induces apoptosis in sensitive and highly resistant multiple myeloma cells. <i>Blood</i> , <b>2005</b> , 105, 1265-73	2.2	61
215	Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 3015-3022	2.2	57
214	A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial. <i>British Journal of Haematology</i> , <b>2016</b> , 172, 535-44	4.5	56
213	A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era. <i>British Journal of Haematology</i> , <b>2014</b> , 165, 358-63	4.5	54
212	Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort. <i>American Journal of Hematology</i> , <b>2015</b> , 90, 778-83	7.1	53
211	A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 1059-66	12.9	52
210	Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2015</b> , 21, 971-83	4.7	51
209	Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project. <i>Cancer</i> , <b>2013</b> , 119, 3662-71	6.4	51

208	Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. <i>Blood</i> , <b>2019</b> , 134, 1238-1246	2.2	50
207	Hematologic Malignancies in Pregnancy: Management Guidelines From an International Consensus Meeting. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 501-8	2.2	49
206	Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities. <i>Blood</i> , <b>2015</b> , 125, 2471-6	2.2	48
205	Hypoxia-inducible factor-1 {alpha} expression predicts superior survival in patients with diffuse large B-cell lymphoma treated with R-CHOP. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 1017-24	2.2	47
204	Motexafin gadolinium: a redox-active tumor selective agent for the treatment of cancer. <i>Current Opinion in Oncology</i> , <b>2004</b> , 16, 576-80	4.2	46
203	PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications. <i>Oncotarget</i> , <b>2016</b> , 7, 59976-59986	3.3	45
202	Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 471-480	2.2	44
201	CD23+ mantle cell lymphoma: a clinical pathologic entity associated with superior outcome compared with CD23- disease. <i>American Journal of Clinical Pathology</i> , <b>2008</b> , 130, 166-77	1.9	44
200	Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event. <i>Blood</i> , <b>2014</b> , 123, 2895-7	2.2	43
199	Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies. <i>American Journal of Hematology</i> , <b>2017</b> , 92, 161-170	7.1	43
198	Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL. <i>Blood Advances</i> , <b>2017</b> , 1, 2600-2609	7.8	43
197	Rituximab-induced late-onset neutropenia in newly diagnosed B-cell lymphoma correlates with Fc receptor FcR3a 158(V/F) polymorphism. <i>American Journal of Hematology</i> , <b>2010</b> , 85, 810-2	7.1	43
196	The immune checkpoint molecules PD-1, PD-L1, TIM-3 and LAG-3 in diffuse large B-cell lymphoma. <i>Oncotarget</i> , <b>2019</b> , 10, 2030-2040	3.3	43
195	A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma. <i>British Journal of Haematology</i> , <b>2008</b> , 140, 385-93	4.5	42
194	Does younger donor age affect the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially?. <i>Bone Marrow Transplantation</i> , <b>2006</b> , 38, 95-100	4.4	41
193	Imexon-induced apoptosis in multiple myeloma tumor cells is caspase-8 dependent. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 1481-91	12.9	41
192	Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 719-26	12.9	40
191	Expression of CD25 independently predicts early treatment failure of acute myeloid leukaemia (AML). <i>British Journal of Haematology</i> , <b>2013</b> , 160, 262-6	4.5	39

190	Fatty Acid Synthase induced S6Kinase facilitates USP11-eIF4B complex formation for sustained oncogenic translation in DLBCL. <i>Nature Communications</i> , <b>2018</b> , 9, 829	17.4	37
189	Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers. <i>Archives of Internal Medicine</i> , <b>2007</b> , 167, 1041-9		37
188	Expression of the candidate MCT-1 oncogene in B- and T-cell lymphoid malignancies. <i>Blood</i> , <b>2003</b> , 102, 297-302	2.2	37
187	A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas. <i>British Journal of Haematology</i> , <b>2013</b> , 163, 55-61	4.5	36
186	Clinical, morphologic, immunophenotypic, and molecular cytogenetic assessment of CD4-/CD8- $\square$ T-cell large granular lymphocytic leukemia. <i>American Journal of Clinical Pathology</i> , <b>2011</b> , 136, 289-99	1.9	36
185	Hypoxia inducible factor-alpha activation in lymphoma and relationship to the thioredoxin family. <i>British Journal of Haematology</i> , <b>2008</b> , 141, 676-80	4.5	35
184	Targeting angiogenesis for the treatment of sarcoma. <i>Current Opinion in Oncology</i> , <b>2006</b> , 18, 354-9	4.2	35
183	Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis. <i>Cancer</i> , <b>2018</b> , 124, 136-144	6.4	34
182	F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma. <i>British Journal of Haematology</i> , <b>2014</b> , 165, 793-800	4.5	34
181	The impact of race, age, and sex in follicular lymphoma: A comprehensive SEER analysis across consecutive treatment eras. <i>American Journal of Hematology</i> , <b>2014</b> , 89, 633-8	7.1	34
180	All trans retinoic acid nanodisks enhance retinoic acid receptor mediated apoptosis and cell cycle arrest in mantle cell lymphoma. <i>British Journal of Haematology</i> , <b>2010</b> , 150, 158-69	4.5	34
179	Obesity and risk of non-Hodgkin lymphoma (United States). <i>Cancer Causes and Control</i> , <b>2007</b> , 18, 677-85	2.8	34
178	Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients. <i>Biology of Blood and Marrow Transplantation</i> , <b>2016</b> , 22, 1543-1551	4.7	34
177	De novo CD5+ diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort. <i>American Journal of Hematology</i> , <b>2016</b> , 91, 395-9	7.1	32
176	A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma. <i>Annals of Oncology</i> , <b>2013</b> , 24, 3076-81	10.3	32
175	Treatment of T-cell non-Hodgkin's lymphoma. <i>Current Treatment Options in Oncology</i> , <b>2004</b> , 5, 289-303	5.4	32
174	Dynamic Analysis of Human Natural Killer Cell Response at Single-Cell Resolution in B-Cell Non-Hodgkin Lymphoma. <i>Frontiers in Immunology</i> , <b>2017</b> , 8, 1736	8.4	31
173	Microfluidic assembly of hydrogel-based immunogenic tumor spheroids for evaluation of anticancer therapies and biomarker release. <i>Journal of Controlled Release</i> , <b>2019</b> , 295, 21-30	11.7	31



172	Hodgkin lymphoma in older patients: an uncommon disease in need of study. <i>Oncology</i> , <b>2008</b> , 22, 1369-708		31
171	The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease. <i>Blood</i> , <b>2014</b> , 124, 3356-64	2.2	30
170	Health-related quality of life in Hodgkin lymphoma: a systematic review. <i>Health and Quality of Life Outcomes</i> , <b>2016</b> , 14, 114	3	29
169	Proteasomal Inhibition by Ixazomib Induces CHK1 and MYC-Dependent Cell Death in T-cell and Hodgkin Lymphoma. <i>Cancer Research</i> , <b>2016</b> , 76, 3319-31	10.1	28
168	The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphoma. <i>Blood</i> , <b>2011</b> , 118, 1052-61	2.2	28
167	Can the stem cell mobilization technique influence CD34+ cell collection efficiency of leukapheresis procedures in patients with hematologic malignancies?. <i>Bone Marrow Transplantation</i> , <b>2005</b> , 35, 243-6	4.4	28
166	Early posttransplant lymphoproliferative disease: clinicopathologic features and correlation with mTOR signaling pathway activation. <i>American Journal of Clinical Pathology</i> , <b>2012</b> , 138, 568-78	1.9	27
165	Optimizing the CD34 + cell dose for reduced-intensity allogeneic hematopoietic stem cell transplantation. <i>Leukemia and Lymphoma</i> , <b>2009</b> , 50, 1434-41	1.9	26
164	Comparative analysis of flow cytometric techniques in assessment of ZAP-70 expression in relation to IgVH mutational status in chronic lymphocytic leukemia. <i>American Journal of Clinical Pathology</i> , <b>2007</b> , 127, 182-91	1.9	26
163	Sun exposure and non-Hodgkin lymphoma: a population-based, case-control study. <i>European Journal of Cancer</i> , <b>2007</b> , 43, 2388-95	7.5	26
162	Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma. <i>Blood</i> , <b>2021</b> , 137, 1318-1326	2.2	25
161	Role of hypoxia in Diffuse Large B-cell Lymphoma: Metabolic repression and selective translation of HK2 facilitates development of DLBCL. <i>Scientific Reports</i> , <b>2018</b> , 8, 744	4.9	24
160	TTP/HUS occurring in a simultaneous pancreas/kidney transplant recipient after clopidogrel treatment: evidence of a nonimmunological etiology. <i>Transplantation</i> , <b>2002</b> , 74, 885-7	1.8	24
159	The impact of race, ethnicity, age and sex on clinical outcome in chronic lymphocytic leukemia: a comprehensive Surveillance, Epidemiology, and End Results analysis in the modern era. <i>Leukemia and Lymphoma</i> , <b>2014</b> , 55, 2778-84	1.9	23
158	Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations. <i>Journal of the National Cancer Institute</i> , <b>2017</b> , 109,	9.7	22
157	Hodgkin lymphoma post-transplant lymphoproliferative disorder: A comparative analysis of clinical characteristics, prognosis, and survival. <i>American Journal of Hematology</i> , <b>2016</b> , 91, 560-5	7.1	22
156	Periodontal disease and risk of non-Hodgkin lymphoma in the Health Professionals Follow-Up Study. <i>International Journal of Cancer</i> , <b>2017</b> , 140, 1020-1026	7.5	22
155	Dietary factors and risk of t(14;18)-defined subgroups of non-Hodgkin lymphoma. <i>Cancer Causes and Control</i> , <b>2008</b> , 19, 859-67	2.8	22

154	Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphoma. <i>Annals of Oncology</i> , <b>2007</b> , 18, 679-88	10.3	22
153	Interaction kinetics with transcriptomic and secretory responses of CD19-CAR natural killer-cell therapy in CD20 resistant non-hodgkin lymphoma. <i>Leukemia</i> , <b>2020</b> , 34, 1291-1304	10.7	22
152	Multiple successful desensitizations to brentuximab vedotin: a case report and literature review. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2014</b> , 12, 465-71	7.3	21
151	Dietary intake of fruit and vegetables and risk of non-Hodgkin lymphoma. <i>Cancer Causes and Control</i> , <b>2011</b> , 22, 1183-95	2.8	20
150	Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study. <i>Blood</i> , <b>2019</b> , 133, 1762-1765	2.2	19
149	C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy. <i>Cancer</i> , <b>2017</b> , 123, 4411-4418	6.4	19
148	Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers. <i>Blood</i> , <b>2021</b> , 137, 374-386	2.2	19
147	Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin lymphoma: a multicentre phase II study. <i>British Journal of Haematology</i> , <b>2014</b> , 166, 514-20	4.5	17
146	Glutathione depletion enhances arsenic trioxide-induced apoptosis in lymphoma cells through mitochondrial-independent mechanisms. <i>British Journal of Haematology</i> , <b>2010</b> , 150, 365-9	4.5	16
145	Clinical characteristics of erythropoietin-associated pure red cell aplasia. <i>Best Practice and Research in Clinical Haematology</i> , <b>2005</b> , 18, 467-72	4.2	16
144	Burkitt's and Burkitt-like lymphoma. <i>Current Treatment Options in Oncology</i> , <b>2002</b> , 3, 291-305	5.4	16
143	Paradoxical regulation of hypoxia inducible factor-1 (HIF-1) by histone deacetylase inhibitor in diffuse large B-cell lymphoma. <i>PLoS ONE</i> , <b>2013</b> , 8, e81333	3.7	16
142	How I manage patients with grey zone lymphoma. <i>British Journal of Haematology</i> , <b>2016</b> , 174, 345-50	4.5	16
141	Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma. <i>British Journal of Haematology</i> , <b>2019</b> , 184, 524-535	4.5	16
140	The Impact of Age and Sex in DLBCL: Systems Biology Analyses Identify Distinct Molecular Changes and Signaling Networks. <i>Cancer Informatics</i> , <b>2015</b> , 14, 141-8	2.4	15
139	Vaccination history and risk of non-Hodgkin lymphoma: a population-based, case-control study. <i>Cancer Causes and Control</i> , <b>2009</b> , 20, 517-23	2.8	15
138	The novel organic arsenical darinaparsin induces MAPK-mediated and SHP1-dependent cell death in T-cell lymphoma and Hodgkin lymphoma cells and human xenograft models. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 6023-33	12.9	14
137	Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: a phase I trial of combined induction therapy and bortezomib consolidation. <i>Leukemia and Lymphoma</i> , <b>2013</b> , 54, 497-502	1.9	13



136	The challenges of epidemiologic research in non-Hodgkin lymphoma. <i>JAMA - Journal of the American Medical Association</i> , <b>2008</b> , 300, 2059-61	27.4	13
135	Relapsed and refractory Hodgkin lymphoma: transplantation strategies and novel therapeutic options. <i>Current Treatment Options in Oncology</i> , <b>2007</b> , 8, 352-74	5.4	13
134	Molecular etiology of mature T-cell non-Hodgkin's lymphomas. <i>Frontiers in Bioscience - Landmark</i> , <b>2003</b> , 8, d156-75	2.8	13
133	The novel expanded porphyrin, motexafin gadolinium, combined with [90Y]ibritumomab tiuxetan for relapsed/refractory non-Hodgkin's lymphoma: preclinical findings and results of a phase I trial. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 6462-71	12.9	12
132	Epoetin-induced pure red-cell aplasia (PRCA): preliminary results from the research on adverse drug events and reports (RADAR) group. <i>Best Practice and Research in Clinical Haematology</i> , <b>2005</b> , 18, 481-9	4.2	12
131	Motexafin gadolinium induces oxidative stress and apoptosis in hematologic malignancies. <i>Current Treatment Options in Oncology</i> , <b>2005</b> , 6, 289-96	5.4	12
130	A Circulating microRNA Signature Predicts Age-Based Development of Lymphoma. <i>PLoS ONE</i> , <b>2017</b> , 12, e0170521	3.7	12
129	Identification of Circulating Serum Multi-MicroRNA Signatures in Human DLBCL Models. <i>Scientific Reports</i> , <b>2019</b> , 9, 17161	4.9	12
128	Chemotherapeutic advancements in peripheral T-cell lymphoma. <i>Seminars in Hematology</i> , <b>2014</b> , 51, 17-24		11
127	Survival Analyses and Prognosis of Plasma-Cell Myeloma and Plasmacytoma-Like Posttransplantation Lymphoproliferative Disorders. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2016</b> , 16, 684-692.e3	2	11
126	The evolving role of response-adapted PET imaging in Hodgkin lymphoma. <i>Therapeutic Advances in Hematology</i> , <b>2016</b> , 7, 108-25	5.7	10
125	XII. Hodgkin lymphoma in older patients: challenges and opportunities to improve outcomes. <i>Hematological Oncology</i> , <b>2013</b> , 31 Suppl 1, 69-75	1.3	10
124	Radioimmunotherapy for the treatment of non-Hodgkin lymphoma: current status and future applications. <i>Leukemia and Lymphoma</i> , <b>2010</b> , 51, 1163-77	1.9	10
123	Comparative oncology DNA sequencing of canine T cell lymphoma via human hotspot panel. <i>Oncotarget</i> , <b>2018</b> , 9, 22693-22702	3.3	10
122	Current therapeutic strategies and new treatment paradigms for follicular lymphoma. <i>Cancer Treatment and Research</i> , <b>2015</b> , 165, 197-226	3.5	9
121	Gray Zone Lymphoma: Current Diagnosis and Treatment Options. <i>Hematology/Oncology Clinics of North America</i> , <b>2016</b> , 30, 1251-1260	3.1	9
120	Sustained hematologic and central nervous system remission with single-agent denileukin diftitox in refractory adult T-cell leukemia/lymphoma. <i>Clinical Lymphoma and Myeloma</i> , <b>2007</b> , 7, 472-4		9
119	A Phase II Multicenter Study of the Histone Deacetylase Inhibitor (HDACi) Abexinostat (PCI-24781) in Relapsed/Refractory Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL). <i>Blood</i> , <b>2012</b> , 120, 55-55	2.2	9

118	The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease. <i>Hematology American Society of Hematology Education Program</i> , <b>2014</b> , 2014, 135-43	3.1	8
117	Brentuximab Vedotin (BV) Plus Rituximab (R) As Frontline Therapy for Patients (Pts) with Epstein Barr Virus (EBV)+ and/or CD30+ Lymphoma: Phase I Results of an Ongoing Phase I-II Study. <i>Blood</i> , <b>2014</b> , 124, 3096-3096	2.2	8
116	Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study. <i>Haematologica</i> , <b>2021</b> , 106, 1932-1942	6.6	8
115	Early-stage Hodgkin lymphoma in the modern era: simulation modelling to delineate long-term patient outcomes. <i>British Journal of Haematology</i> , <b>2018</b> , 182, 212-221	4.5	7
114	Proton irradiation impacts age-driven modulations of cancer progression influenced by immune system transcriptome modifications from splenic tissue. <i>Journal of Radiation Research</i> , <b>2015</b> , 56, 792-803 <sup>2,4</sup>		7
113	Pre-diagnosis cigarette smoking and overall survival in non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , <b>2013</b> , 163, 352-6	4.5	7
112	Older Patients (pts) with Previously Untreated Classical Hodgkin Lymphoma (cHL): A Detailed Analysis from the Phase 3 ECHELON-1 Study. <i>Blood</i> , <b>2018</b> , 132, 1618-1618	2.2	7
111	Burkitt Lymphoma International Prognostic Index. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 1129-1138	2.2	7
110	Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study. <i>Leukemia and Lymphoma</i> , <b>2019</b> , 60, 894-903	1.9	7
109	FDG-PET imaging for Hodgkin lymphoma: current use and future applications. <i>Clinical Advances in Hematology and Oncology</i> , <b>2014</b> , 12, 20-35	0.6	7
108	Impact Of Induction Regimen and Consolidative Stem Cell Transplantation In Patients With Double Hit Lymphoma (DHL): A Large Multicenter Retrospective Analysis. <i>Blood</i> , <b>2013</b> , 122, 640-640	2.2	6
107	Effect of bortezomib on complete remission (CR) rate when added to bendamustine-rituximab (BR) in previously untreated high-risk (HR) follicular lymphoma (FL): A randomized phase II trial of the ECOG-ACRIN Cancer Research Group (E2408).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 7507-7507	2.2	5
106	HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis. <i>Blood Advances</i> , <b>2021</b> , 5, 2852-2862	7.8	5
105	A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 4468-4477	12.9	4
104	First-line treatment in older patients with Hodgkin lymphoma: a Surveillance, Epidemiology, and End Results (SEER)-Medicare population-based study. <i>British Journal of Haematology</i> , <b>2020</b> , 190, 222-235 <sup>4,5</sup>		4
103	Radioimmunotherapy in non-Hodgkin's lymphoma: trials of yttrium 90-labeled ibritumomab tiuxetan and beyond. <i>Clinical Lymphoma and Myeloma</i> , <b>2004</b> , 5 Suppl 1, S11-5		4
102	Phase I Analysis of the Safety and Pharmacodynamics of the Novel Broad Spectrum Histone Deacetylase Inhibitor (HDACi) PCI-24781 in Relapsed and Refractory Lymphoma.. <i>Blood</i> , <b>2009</b> , 114, 2726-2726 <sup>2,3</sup>		4
101	The Lipid Addiction of Diffuse Large B-Cell Lymphoma (DLBCL) and Potential Treatment Strategies with Novel Fatty Acid Synthase (FASN) Small Molecule Inhibitors. <i>Blood</i> , <b>2014</b> , 124, 4490-4490	2.2	4

100	Patient-Derived Xenografts (PDX) of B Cell Lymphoma in NSG Mice: A Mouse Avatar for Developing Personalized Medicine. <i>Blood</i> , <b>2015</b> , 126, 5408-5408	2.2	4
99	Paraneoplastic pyoderma gangrenosum with posttransplant lymphoproliferative disorder. <i>Annals of Hematology</i> , <b>2015</b> , 94, 893-4	3	3
98	Primary mediastinal large B-cell lymphoma in HIV: report of two cases. <i>Journal of Hematopathology</i> , <b>2009</b> , 2, 45-9	0.4	3
97	Curing Hodgkin's lymphoma: quantity and quality. <i>Lancet Oncology, The</i> , <b>2009</b> , 10, 1134-5	21.7	3
96	Lymphoma in Pregnancy: Excellent Fetal Outcomes and Maternal Survival in a Large Multicenter Analysis. <i>Blood</i> , <b>2011</b> , 118, 94-94	2.2	3
95	Splenic Irradiation and a Reduced-Intensity Conditioning Regimen Prior to Allogeneic Stem-Cell Transplantation for Myelofibrosis. <i>Blood</i> , <b>2014</b> , 124, 3170-3170	2.2	3
94	Management of older Hodgkin lymphoma patients. <i>Hematology American Society of Hematology Education Program</i> , <b>2019</b> , 2019, 233-242	3.1	3
93	SARS-CoV-2 nosocomial infection: Real-world results of environmental surface testing from a large tertiary cancer center. <i>Cancer</i> , <b>2021</b> , 127, 1926-1932	6.4	3
92	Current Treatment Options for Older Patients with Hodgkin Lymphoma. <i>Current Treatment Options in Oncology</i> , <b>2020</b> , 21, 42	5.4	2
91	University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL. <i>British Journal of Haematology</i> , <b>2018</b> , 181, 264-267	4.5	2
90	The Novel 2nd Generation Small Molecule MEK Inhibitor, AZD-6244, Induces Cell Death in Lymphoma Cells Lines, Primary Cells, and in a Human Lymphoma Xenograft Model.. <i>Blood</i> , <b>2009</b> , 114, 285-285	2.2	2
89	Results of a Prospective Multicenter Phase II Study of Initial Treatment with Methotrexate In LGL Leukemia (ECOG Protocol E5998). <i>Blood</i> , <b>2010</b> , 116, 702-702	2.2	2
88	Primary Central Nervous System (PCNS) Post-Transplant Lymphoproliferative Disease (PTLD): An International Report of 65 Cases in the Modern Era. <i>Blood</i> , <b>2011</b> , 118, 879-879	2.2	2
87	Primary Breast Diffuse Large B Cell Lymphoma: A Distinct Clinical Entity. <i>Blood</i> , <b>2012</b> , 120, 1618-1618	2.2	2
86	Targeting The Interactions Of Fatty Acid Metabolism With PI3K/mTOR and MAPK As a Novel Therapeutic Strategy In Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , <b>2013</b> , 122, 5133-5133	2.2	2
85	Oncogenic Integration of Nucleotide Metabolism Fatty Acid Synthase in Non-Hodgkin Lymphoma. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 725137	5.3	2
84	The Bruton Tyrosine Kinase Inhibitor CC-292 in Diffuse Large B-Cell Lymphoma (DLBCL), T-Cell Lymphoma (TCL), and Hodgkin Lymphoma (HL): Induction of Cell Death and Examination of Rational Novel/Novel Therapeutic Combinations. <i>Blood</i> , <b>2014</b> , 124, 1772-1772	2.2	2
83	Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin. <i>Leukemia and Lymphoma</i> , <b>2019</b> , 60, 940-946	1.9	2

82	Combinatorial ixazomib and belinostat therapy induces NFE2L2-dependent apoptosis in Hodgkin and T-cell lymphoma. <i>British Journal of Haematology</i> , <b>2020</b> , 188, 295-308	4.5	2
81	Assessing the risk of cardiac toxicity after contemporary treatment for Hodgkin lymphoma: a systematic review. <i>Leukemia and Lymphoma</i> , <b>2018</b> , 59, 1976-1980	1.9	2
80	Patterns of Failure and Survival Outcomes after Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Relapsed or Refractory Classical Hodgkin Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2019</b> , 104, 436-446	4	1
79	How I treat advanced Hodgkin lymphoma - a global view. <i>British Journal of Haematology</i> , <b>2020</b> , 190, 837-850	4.5	1
78	Reply to D. Dierickx et al. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, e367-e368	2.2	1
77	Long-Term Follow-Up of Recombinant Human Erythropoietin (epoetin)Induced Pure Red Cell Aplasia (PRCA): A Comparison of Data Collected through Active and Passive Pharmacovigilance Efforts.. <i>Blood</i> , <b>2004</b> , 104, 5319-5319	2.2	1
76	Glutathione Depletion Enhances Arsenic Trioxide-Induced Apoptosis in Lymphoma Cells through Mitochondrial and Caspase-Independent Mechanisms.. <i>Blood</i> , <b>2009</b> , 114, 2708-2708	2.2	1
75	Mitochondrial-Mediated Apoptosis in Lymphoma by the Diterpenoid Lactone Andrographolide (Andro), the Active Component of <i>Andrographolis Paniculata</i> .. <i>Blood</i> , <b>2009</b> , 114, 2710-2710	2.2	1
74	A Phase I/II Trial of Combination Gemcitabine and Bortezomib (VELCADE®) for Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma (NHL) and Aggressive B-Cell NHL. <i>Blood</i> , <b>2011</b> , 118, 1646-1646	2.2	1
73	Multicenter Analysis of Elderly Hodgkin Lymphoma (eHL): Outcomes and Prognostic Factors in the Modern Era. <i>Blood</i> , <b>2011</b> , 118, 2625-2625	2.2	1
72	A Phase 2 Clinical Trial Adding Rituximab to CODOX-M/IVAC for Untreated Burkitts Lymphoma: Correlative Analysis of Serum and CSF Rituximab Levels. <i>Blood</i> , <b>2012</b> , 120, 1640-1640	2.2	1
71	Hodgkin Lymphoma Type Post-Transplant Lymphoproliferative Disorder (HL-PTLD) after Solid Organ Transplant (SOT): A Comprehensive and Comparative Analysis of Disease Characteristics, Prognosis, and Survival. <i>Blood</i> , <b>2014</b> , 124, 502-502	2.2	1
70	Association of Treatment Intensity With Survival in Older Patients With Hodgkin Lymphoma. <i>JAMA Network Open</i> , <b>2021</b> , 4, e2128373	10.4	1
69	Optimizing Decision Making in Hodgkin Lymphoma. <i>Hematologic Malignancies</i> , <b>2020</b> , 265-273	0	1
68	Strand-Specific Total RNA Sequencing Establishes the Complete Transcriptome and Alternative Splicing Repertoire in Diffuse Large B Cell Lymphoma. <i>Blood</i> , <b>2014</b> , 124, 864-864	2.2	1
67	PX-478, a Novel Small Molecule Inhibitor of Hypoxia Inducible Factor-1 (HIF-1) Downregulates HIF and Induces Cytotoxicity in Diffuse Large B Cell Lymphoma Cells.. <i>Blood</i> , <b>2009</b> , 114, 2713-2713	2.2	1
66	Outcomes with Autologous (Auto) and Allogeneic (Allo) Stem Cell Transplantation (SCT) for Relapsed/Refractory Follicular Lymphoma (FL) in the Post-Rituximab Era: A Comparative Analysis From the National Comprehensive Cancer Network (NCCN) Non-Hodgkin's Lymphoma (NHL) Outcomes Database Project.. <i>Blood</i> , <b>2011</b> , 118, 4112-4112	2.2	1
65	Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma. <i>Blood Advances</i> , <b>2021</b> , 5, 3623-3632	7.8	1

64	A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomas. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 1-8	1.9	1
63	Survivorship transition care experiences and preparedness for survivorship among a diverse population of cancer survivors in New Jersey.. <i>European Journal of Cancer Care</i> , <b>2022</b> , e13553	2.4	1
62	Treatment Strategies for Advanced Classical Hodgkin Lymphoma in the Times of Dacarbazine Shortage.. <i>JCO Oncology Practice</i> , <b>2022</b> , OP2100890	2.3	1
61	Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary analysis of SWOG S0816. <i>Leukemia and Lymphoma</i> , <b>2020</b> , 61, 2442-2447	1.9	0
60	A systematic review of therapeutic regimens for older patients with newly diagnosed Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , <b>2020</b> , 61, 1555-1564	1.9	0
59	T-Cell Non-Hodgkin Lymphoma <b>2006</b> , 161-220		0
58	Fatty Acid Metabolism in Diffuse Large B-Cell Lymphoma (DLBCL): Interaction with Oncogenic Cell Signaling Pathways and the Identification of a Novel Treatment Paradigm.. <i>Blood</i> , <b>2012</b> , 120, 2711-2711	2.2	0
57	Lymphoma Occurring During Pregnancy: Current Diagnostic and Therapeutic Approaches. <i>Current Oncology Reports</i> , <b>2020</b> , 22, 113	6.3	0
56	Development and validation of a prediction model for 1-year mortality among older adults with Hodgkin Lymphoma who receive dose-intense chemotherapy. <i>Journal of Geriatric Oncology</i> , <b>2021</b> , 12, 1233-1239	3.6	0
55	Toxicities, response and survival: Autologous stem cell transplantation for multiple myeloma over 25 years at a single center. <i>Cancer Treatment and Research Communications</i> , <b>2017</b> , 11, 1-5	2	
54	Does Q fever contribute to pathogenesis of non-Hodgkin lymphoma?. <i>Lancet Haematology</i> , <b>2018</b> , 5, e186-e187	14.6	
53	T-cell non-Hodgkin lymphoma 226-253		
52	T-cell lymphoma <b>2001</b> , 215-232		
51	Comparative Analysis of Flow Cytometric Techniques in Assessment of ZAP-70 Expression in Relation to IgV H Mutational Status in Chronic Lymphocytic Leukemia. <i>American Journal of Clinical Pathology</i> , <b>2007</b> , 127, 182-191	1.9	
50	Dramatic and Sustained Hematologic Complete Remission with Denileukin Diftitox (ONTAK <sup>®</sup> ) in a Patient with Refractory Adult T-Cell Leukemia (ATL).. <i>Blood</i> , <b>2005</b> , 106, 4638-4638	2.2	
49	Combination of Motexafin Gadolinium (MGd) with 90Y Ibritumomab Tiuxetan (Zevalin <sup>®</sup> ; 90Yttrium-Zevalin) Radioimmunotherapy (RIT) Produces High Complete Remission Rates in Relapsed Rituximab-Refractory Follicular Non- Hodgkin Lymphoma (NHL).. <i>Blood</i> , <b>2005</b> , 106, 2450-2450	2.2	
48	Thalidomide-Associated Thromboembolism in Cancer: Reimbursement for Thalidomide Off-Label Prescribing under the 2004 Medicare Oral Pharmaceutical Demonstration Project Raises Concerns.. <i>Blood</i> , <b>2005</b> , 106, 2244-2244	2.2	
47	Allogeneic Stem Cell Transplantation (AlloSCT) for Relapsed Hodgkin Lymphoma (HL) Following Autologous Stem Cell Transplantation (AuSCT): Improved Progression-Free Survival (PFS) in Patients with Graft vs Host-Disease (GvHD) Suggests a Graft vs Lymphoma (GVL) Effect.. <i>Blood</i> , <b>2005</b> , 106, 5155-5155	2.2	



- 46 Comparison of Out-of-Pocket Costs and Quality of Life (QOL) for Patients (pts) with Hodgkin Disease (HD), Indolent Non-Hodgkin Lymphoma (INHL) and Aggressive Non-Hodgkin Lymphoma (ANHL).. *Blood*, **2006**, 108, 3332-3332 2.2
- 45 Hypoxia-Inducible Factor-Alpha (HIF- $\alpha$ ) Activation in Non-Hodgkin Lymphoma (NHL): Relationship to the Thioredoxin Family and Correlation with Survival by Tissue Microarray (TMA).. *Blood*, **2007**, 110, 3587-3587 2.2
- 44 Longitudinal toxicity analysis with novel summary metrics of lenalidomide maintenance in follicular lymphoma in ECOG-ACRIN 2408.. *Journal of Clinical Oncology*, **2019**, 37, 6511-6511 2.2
- 43 The Management of Older Patients with Hodgkin Lymphoma. *Hematologic Malignancies*, **2020**, 297-315 ○
- 42 Hodgkin lymphoma-like post-transplant lymphoproliferative disorder (HL-PTLD): Characteristics, survival, and prognostication in a large U.S. cohort.. *Journal of Clinical Oncology*, **2014**, 32, 8572-8572 2.2
- 41 Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumor burden (HTB) indolent non-Hodgkin lymphoma (iNHL): A multicenter phase II study.. *Journal of Clinical Oncology*, **2014**, 32, 8545-8545 2.2
- 40 Peripheral T-cell lymphomas (PTCL) in the modern era: Prognosis and impact of therapy in a large U.S. multicenter cohort.. *Journal of Clinical Oncology*, **2014**, 32, e19561-e19561 2.2
- 39 The Management of Older Patients with Hodgkin Lymphoma. *Hematologic Malignancies*, **2015**, 271-286 ○
- 38 Photopheresis As Part of Conditioning Reduces Incidence of Severe Graft Versus Host Disease: Fourteen Year Follow-up of a Novel Reduced Intensity Regimen for Allogeneic Hematopoietic Stem Cell Transplantation. *Blood*, **2014**, 124, 5924-5924 2.2
- 37 Gray Zone Lymphoma (GZL) with Features Intermediate Between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of Tumor Immunophenotype (IP) and Critical Examination of Therapy with Associated Impact on Outcome. *Blood*, **2014**, 124, 1703-1703 2.2
- 36 Genome-Wide Analysis Reveals MYC-Dependent Cell Death and Identifies Predictive Biomarkers of Ixazomib Sensitivity in Preclinical Models of T-Cell Lymphoma (TCL) and Hodgkin Lymphoma (HL). *Blood*, **2014**, 124, 3120-3120 2.2
- 35 Hepatitis B (HBV) Screening in Patients Receiving Rituximab: A Comprehensive Analysis Including Comparison of Adherence By Oncologists and Non-Oncologists. *Blood*, **2014**, 124, 2595-2595 2.2
- 34 A Comparative Oncology Study of Canine and Human Genomics and Proteomics in Peripheral T-Cell Lymphoma (PTCL): Examination of Shared Oncogenic Signaling for Biomarker and Therapeutic Target Discovery. *Blood*, **2014**, 124, 3019-3019 2.2
- 33 An Adjustable Markov Model to Project Life Expectancy (LE) for Early Stage Favorable Risk Hodgkin Lymphoma Patients Treated with Contemporary Therapy. *Blood*, **2015**, 126, 2635-2635 2.2
- 32 Periodontal Disease and Risk of Non Hodgkin Lymphoma (NHL) in the Health Professionals Follow-up Study (HPFS). *Blood*, **2015**, 126, 5024-5024 2.2
- 31 A Comparative Oncology Analysis of Canine T-Cell Lymphoma (TCL): Immunohistochemical Study and Next Generation Sequencing for Protein Analysis and Genomic Target Discovery. *Blood*, **2015**, 126, 3883-3883 2.2
- 30 Managing Lymphoma During Pregnancy **2016**, 159-173
- 29 Health-related quality of life (HRQL) in Hodgkin lymphoma (HL): A systematic review (SR).. *Journal of Clinical Oncology*, **2016**, 34, 234-234 2.2



28	Circulating microRNAs Predict the Initiation of NHL in a Novel In Vivo Model: Impact of Age and Sex Via a Systems Biology Approach. <i>Blood</i> , <b>2016</b> , 128, 4114-4114	2.2
27	All Trans Retinoic Acid Nanodisks Enhance Retinoic Acid Receptor-Mediated Apoptosis and Cell Cycle Arrest in Mantle Cell Lymphoma.. <i>Blood</i> , <b>2009</b> , 114, 3722-3722	2.2
26	A Comprehensive Identification of the MicroRNA Transcriptome and Its Application in B Cell Malignancies.. <i>Blood</i> , <b>2009</b> , 114, 2403-2403	2.2
25	Burkitt Lymphoma and Leukemia <b>2011</b> , 175-210	
24	Alternative Splicing Is a Major Mechanism of Gene Regulation In Diffuse Large B Cell Lymphoma. <i>Blood</i> , <b>2010</b> , 116, 803-803	2.2
23	Multicenter Analysis of 150 Very Elderly Non-Hodgkin’s Lymphoma (NHL) Patients: Impact of Comorbidities and Response to Initial Therapy on Survival. <i>Blood</i> , <b>2010</b> , 116, 3124-3124	2.2
22	Whole Genome and Exome Sequencing Reveals the Genetic Landscape of Burkitt Lymphoma. <i>Blood</i> , <b>2011</b> , 118, 433-433	2.2
21	Multicenter Analysis of Very Elderly Indolent and Aggressive Non-Hodgkin Lymphoma (NHL): Impact of Functional Status on Outcome.,. <i>Blood</i> , <b>2011</b> , 118, 3668-3668	2.2
20	Integration of Rituximab and Liposomal Doxorubicin (DOXIL <sup>®</sup> ) Into CODOX-M/IVAC for HIV-Negative and HIV+ Adults with Untreated Burkitt’s Lymphoma (BL): Results of a Prospective Multicenter Phase II Study. <i>Blood</i> , <b>2011</b> , 118, 2669-2669	2.2
19	Busulfan, Cyclophosphamide, and Etoposide (Bu/Cy/VP-16) Is An Effective Conditioning Regimen Prior to Allogeneic or Autologous Stem Cell Transplantation for Primary Refractory or Relapsed Non-Hodgkin’s Lymphoma. <i>Blood</i> , <b>2011</b> , 118, 4499-4499	2.2
18	Characteristics and outcomes of extranodal NK/t-cell lymphoma (ENKL): A North American (NA) multi-institutional experience.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 8060-8060	2.2
17	The incorporation of rituximab (R) and liposomal doxorubicin (LD) into CODOX-m/IVAC for untreated Burkitt lymphoma (BL): Final results of a prospective multicenter phase II study.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 8080-8080	2.2
16	The impact of race, age, and sex in follicular lymphoma (FL): A comprehensive SEER analysis in the pre- and post-rituximab (R) eras.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 8072-8072	2.2
15	Darinaparsin in T-Cell Lymphoma (TCL) and Hodgkin Lymphoma (HL) Cells Lines and SCID Xenograft Mouse Models: Single-Agent Activity and Synergistic Cell Death Combined with a PI3K/mTOR Inhibitor. <i>Blood</i> , <b>2012</b> , 120, 1646-1646	2.2
14	Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Blood Stem-Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma: Excellent Disease Control and Long-Term Survival Rates. <i>Blood</i> , <b>2012</b> , 120, 2024-2024	2.2
13	The Impact of Race, Age, and Sex in Chronic Lymphocytic Leukemia (CLL): A Comprehensive SEER Analysis in the Pre and Post Rituximab (R) Eras.. <i>Blood</i> , <b>2012</b> , 120, 2877-2877	2.2
12	Hepatitis B Virus (HBV) Screening in Hematology/Oncology Patients Who Receive Rituximab: Continued Need for Evidence-Based Standardized Recommendations and Effective Implementation Into Clinical Practice. <i>Blood</i> , <b>2012</b> , 120, 970-970	2.2
11	A Multicenter Phase II Clinical Trial of Rituximab Combined with Bortezomib (VELCADE <sup>®</sup> ) Therapy for Untreated High Tumor Burden Indolent Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , <b>2012</b> , 120, 1642-1642 <sup>2.2</sup>	2.2

10	Diffuse Large B-Cell Lymphomas Utilize Endogenous and Exogenous Fatty Acids for Cell Growth and Survival. <i>Blood</i> , <b>2012</b> , 120, 1581-1581	2.2
9	The 2nd Generation Proteasome Inhibitor, MLN2238: Potent Induction of Cell Death in T-Cell Lymphoma (TCL) and Hodgkin Lymphoma (HL) Cell Lines and in Two Human Lymphoma Xenograft Models.. <i>Blood</i> , <b>2012</b> , 120, 2767-2767	2.2
8	The Impact of Race, Age, and Sex in Follicular Lymphoma (FL): A Comprehensive SEER Analysis in the Pre- and Post-Rituximab Eras. <i>Blood</i> , <b>2012</b> , 120, 1576-1576	2.2
7	Survival of Newly Diagnosed T-Cell Lymphoma (TCL) in the Modern Era: Investigation of Prognostic Factors with Critical Examination of Therapy in a Multicenter US Cohort.. <i>Blood</i> , <b>2012</b> , 120, 2728-2728	2.2
6	Influence of Lifestyle Factors On Expression of Tumor-Related Microenvironment T-Cells and Impact On Survival of Follicular Lymphoma (FL).. <i>Blood</i> , <b>2012</b> , 120, 2694-2694	2.2
5	The Impact of Cigarette Smoking On Overall Survival in Non-Hodgkin Lymphoma. <i>Blood</i> , <b>2012</b> , 120, 5100-5100	2.2
4	ID3 Is a Novel Tumor Suppressor Gene in Burkitt Lymphom. <i>Blood</i> , <b>2012</b> , 120, 898-898	2.2
3	Allogeneic and autologous stem cell transplantation with busulfan, cyclophosphamide, and etoposide conditioning therapy for relapsed/refractory non-Hodgkin lymphoma. <i>Modern Chemotherapy</i> , <b>2013</b> , 02, 57-65	
2	Improving outcomes in PTLD. <i>Oncology</i> , <b>2010</b> , 24, 944, 946-7	1.8
1	Hodgkin lymphoma: epidemiology, diagnosis, and treatment367-403	